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Background: The B-type natriuretic peptides (brain natriuretic peptide [BNP] and its amino terminal pro-BNP [NT-proBNP]) are powerful 
predictors of adverse cardiovascular outcomes in patients with coronary artery disease (CAD). However, their relative prognostic utility remains 
uncertain. We compared the ability of BNP and NT-proBNP to predict cardiovascular events or death in patients with stable CAD.
Methods: We studied the relative prognostic utility of BNP and NT-proBNP in 983 participants with stable CAD from the Heart and Soul Study. The 
primary outcome was time to non-fatal myocardial infarction, hospitalization for congestive heart failure, stroke, transient ischemic attack or death.
Results: During an average of 6.3 ± 3.2 years follow-up, there were 451 events. BNP and NT-proBNP levels were strongly correlated with one 
another (r=0.87; p<0.001). In demographically-adjusted models, NT-proBNP (HR for quartile IV vs. I: 4.15; 95% C.I. 3.08 - 5.59; p<0.001) predicted 
cardiovascular events or death more strongly than BNP (HR for quartile IV vs. I: 3.12; 95% C.I. 2.32 - 4.21; p<0.001). This finding persisted after 
adjustment for traditional coronary risk factors, left ventricular (LV) systolic and diastolic function and LV mass index, with NT-proBNP (HR for 
quartile IV vs. I: 3.22; 95% C.I. 2.18 - 4.74; p<0.001) continuing to predict the primary outcome more strongly than BNP (HR for quartile IV vs. I: 
2.38; 95% C.I. 1.63 - 3.49; p<0.001). When entered as continuous variables in fully adjusted models, NT-proBNP was superior to BNP (AUC 0.80 vs. 
0.78; p<0.01 for comparison) for predicting cardiovascular events or death.
Conclusions: Although secreted in equimolar amounts, NT-proBNP was superior to BNP for predicting cardiovascular events or death in patients 
with stable CAD, independent of other prognostic markers. This likely reflects significant differences in their biological half-lives, in vitro stability, 
mechanisms of clearance and the cross-reactivity of each assay with the proBNP peptides.
